The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1847-1853

  Litière, Saskia ^a   De Vries, Elisabeth G E ^b   Seymour, Lesley ^c   Sargent, Dan ^d   Shankar, Lalitha ^e   Bogaerts, Jan ^a  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Clinical Trials Group   (Canada)

^d MAYO CLINIC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Breast cancer; Colorectal cancer; Goodness of fit; Lung cancer; Time dependent model; Tumour growth

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CHI SQUARE TEST; COLORECTAL CANCER; DATA BASE; FOLLOW UP; HUMAN; LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE EVALUATION CRITERIA IN SOLID TUMOR 1.1 DATABASE;

BREAST CANCER; COLORECTAL CANCER; GOODNESS-OF-FIT; LUNG CANCER; TIME-DEPENDENT MODEL; TUMOUR GROWTH;

AREA UNDER CURVE; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84901789986     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.014     Document Type: Article

References (10)

1. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No 48; 1979.
2. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumours (RECIST Guidelines) J Natl Cancer Inst 92 2000 205 216
3. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
4. J. Bogaerts, R. Ford, and D. Sargent et al. Individual patient data analysis to assess modifications to the RECIST criteria Eur J Cancer 45 2009 248 260
5. P.J. Heagerty, and Y. Zheng Survival predictive accuracy and ROC curves Biometrics 61 2005 92 105
6. P. Cortazar, L. Zhang, and M. Untch et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 2014 10.1016/S0140-6736(08)61345-8
7. H. Bonnefoi, S. Litière, and M. Piccart et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Ann Oncol 2014 10.1093/annonc/mdu118
8. C. Bernard-Marty, F. Cardoso, and M.J. Piccart Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 2004 617 632
9. L.E. Dodd, E.L. Korn, and B. Freidlin et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26 2008 3791 3796
10. J.E. Dancey, L.E. Dodd, and R. Ford et al. Recommendations for the assessment of progression in randomised cancer treatment trials Eur J Cancer 45 2009 281 289